Heparin-induced thrombocytopenia: An estimate of the average cost in the hospital setting in france

Clinical and Applied Thrombosis/Hemostasis

Volumn 15, Issue 4, 2009, Pages 428-434

  Elalamy, Ismail ^a   Le Gal, Gregoire ^b   Nachit Ouinekh, Fatima ^f   Lafuma, Antoine ^c   Emery, Corinne ^c   Le Fur, Camille ^d   Chapuis, François ^e  

^a HÔPITAL TENON   (France)

^b BREST UNIVERSITY HOSPITAL   (France)

^c CEMKA EVAL   (France)

^d GLAXOSMITHKLINE   (Germany)

^e UNIVERSITÉ LYON 1   (France)

^f GLAXOSMITHKLINE   (France)

Author keywords

Cost; Heparin; Thrombocytopenia

Indexed keywords

ARTICLE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; HEPARIN INDUCED THROMBOCYTOPENIA; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SENSITIVITY ANALYSIS;

ACADEMIC MEDICAL CENTERS; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; DATABASES, FACTUAL; FEMALE; FRANCE; HEALTH EXPENDITURES; HEPARIN; HOSPITAL COSTS; HOSPITALIZATION; HUMANS; LENGTH OF STAY; MALE; RISK FACTORS; THROMBOCYTOPENIA;

EID: 69749095678     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029608319441     Document Type: Article

References (13)

1. Warkentin TE Think of HIT. Hematology Am Soc Hematol Educ Program. 2006: 408-414.
2. Amiral J., Bridey F., Dreyfus M., et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost. 1992 ; 68: 95-96.
3. Warkentin TE, Sheppard JA, Horsewood P., Simpson PJ, Moore JC, Kelton JG Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood. 2000 ; 96: 1703-1708.
4. Girolami B., Prandoni P., Stefani PM, et al. The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood. 2003 ; 101: 2955-2959.
5. Gruel Y. Heparin-induced thrombocytopenia, Pathogenesis, diagnosis and treatment [in French]. Rev Med Interne. 2004 ; 25: 35-45.
6. Prandoni P., Siragusa S., Girolami B., Fabris F. The incidence of heparin-induced thrombocytopenia in medical patients treated with low molecular weight heparin. Blood. 2005 ; 106: 3049-3054.
7. Warkentin TE, Maurer BT, Aster RH Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med. 2007 ; 356: 2653-2655.
8. Warkentin TE, Sheppard JA, Sigouin CS, Kohlmann T., Eichler P., Greinacher A. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood. 2006 ; 108: 2937-2941.
9. Creekmore FM, Oderda GM, Pendleton RC, Brixner DI Incidence and economic implications of heparin-induced thrombocytopenia in medical patients receiving prophylaxis for venous thromboembolism. Pharmacotherapy. 2006 ; 26: 1438-1445.
10. Happe LE, Farrelly EM, Stanford RH, Sarnes MW Cost and occurrence of thrombocytopenia in patients receiving venous thromboembolism prophylaxis following major orthopaedic surgeries. J Thromb Thrombolysis. 2007. Available at: http://www.springerlink.com/content/6540552452t4380l/. Accessed April 24, 2008.
11. International Statistical Classification of Diseases and Related Health Problems. Available at: http://www.icd10.ch/index.asp?lang=EN. Accessed: April 24, 2008.
12. Agence Technique de l'Information sur l'Hospitalisation. Available at: http://www.atih.sante.fr/. Accessed: April 24, 2008.
13. Société française d'anesthésie et de réanimation, Groupe d'étude hémostase et thrombose de la Société française d'hématologie, Société française de cardiologie, Société de réanimation de langue française. Thrombopénie induite par l'héparine Conférence d'experts. Paris, 2002. Available at: http://www.sfar.org/s/IMG/pdf/tihconfexp.pdf. Accessed: April 24, 2008.